title: Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients.
abstract: Concern has been raised regarding the response to vaccination in solid organ transplant recipients (SOTR) undergoing immunosuppressant regimens and the possibility of rejection related to the immune response associated with pandemic influenza H1N1-2009 vaccination. The goal of this study was to assess the immunogenicity, efficacy and safety of the pandemic vaccine in SOTR. We performed a multicenter prospective study in SOTR receiving the pandemic vaccine. Immunological response was determined in serum 5 weeks after vaccination by microneutralization assays, and immunoglobulins were measured by ELISA. Three hundred and forty-six SOTR were included. Preexisting seroprotection was detected in 13.6% of cases and rates of seroconversion and seroprotection after vaccination were 73.1% and 82.9%, respectively. Patients with baseline antibody titers had better geometric mean titers (GMT)-post after pandemic vaccination (339.4 vs. 121.4, p < 0.001). Younger age, liver disease and m-TOR inhibitor therapy were independently associated with lower seroprotection and GMT-post. There were no major adverse effects or rejection episodes. Pandemic vaccine was safe in SOTR and elicited an adequate response, although lower than in healthy individuals. This is the first study describing a decreased response after vaccination in patients receiving mTOR inhibitors who presented lower seroprotection rates and lower GMT-post.
authors.affiliation: Unit of Infectious Disease, Microbiology and Preventive Medicine, Institute of Biomedicine of Sevilla (IBiS), University Hospital Virgen del Roc´ıo/CSIC/University of Sevilla, Sevilla, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Cordero
authors.forename: A
authors.initials: A
authors.lastname: Perez-Ordoñez
authors.forename: T A
authors.initials: TA
authors.lastname: Aydillo
authors.forename: J
authors.initials: J
authors.lastname: Torre-Cisneros
authors.forename: J
authors.initials: J
authors.lastname: Gavalda
authors.forename: R
authors.initials: R
authors.lastname: Lara
authors.forename: C
authors.initials: C
authors.lastname: Segura
authors.forename: O
authors.initials: O
authors.lastname: Len
authors.forename: E
authors.initials: E
authors.lastname: Cabral
authors.forename: A
authors.initials: A
authors.lastname: Gasch
authors.forename: J
authors.initials: J
authors.lastname: Pachon
authors.forename: P
authors.initials: P
authors.lastname: Perez-Romero
mesh_terms: D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D008297:Male; D009500:Neutralization Tests; D016377:Organ Transplantation; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D007166:Immunosuppressive Agents; D007252:Influenza Vaccines; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases